First and only subcutaneous anti-CD38 therapy demonstrating potential to prevent end-organ damage, and extend progression-free survival and overall survival based on findings from Phase 3 AQUILA study SAN DIEGO, Dec. 8, 2024 /PRNewswire/ — Johnson & Johnson (NYSE: JNJ) today announced…

SAN DIEGO, Dec. 8, 2024 /PRNewswire/ — Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of The Toronto-Dominion Bank (“TD Bank”) (NYSE: TD) securities between February 29, 2024 and October 9, 2024, inclusive (the “Class Period”), have until Monday, December 23,…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.